

Table S1. The association between severity of work and daily life interference and expression of each adverse effect after BNT162b2 vaccination.

	Interference in work			Interference in daily life	
	Total	Low (0–4)	High (5–10)	Low (0–4)	High (5–10)
	(N=41)	(N=26)	(N=15)	(N=26)	(N=15)
Fever	17 (41.5%)	4 (15.4%)	13 (86.7%)	2 (7.7%)	15 (100.0%)
Chills	16 (39.0%)	4 (15.4%)	12 (80.0%)	4 (15.4%)	12 (80.0%)
Local pain	28(68.3%)	16 (61.5%)	12 (80.0%)	15 (57.7%)	13 (86.7%)
Myalgia	16 (39.0%)	3 (11.5%)	13 (86.7%)	3 (11.5%)	13 (86.7%)
Headache	13 (31.7%)	3 (11.5%)	10 (66.7%)	3 (11.5%)	10 (66.7%)
Nausea	3 (7.3%)	0 (0.0%)	3 (20.0%)	0 (0.0%)	3 (20.0%)
Vomiting	1 (2.4%)	0 (0.0%)	1 (6.7%)	0 (0.0%)	1 (6.7%)
Urticaria	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Dyspnea	1 (2.4%)	0 (0.0%)	1 (6.7%)	0 (0.0%)	1 (6.7%)
Chest pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Degree of total adverse effects	3.7 ± 2.6	2.3 ± 2.0	6.2 ± 1.6	2.2 ± 1.9	6.1 ± 1.7

The degree of total adverse effects was assessed using a 0–10 numeric scale.

Abbreviations: OR, odds ratio; CI, confidence interval